Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Executive Summary
Bristol-Myers Squibb will undertake a cost-cutting program to offset the impact of the development delay of the investigational type 2 diabetes drug Pargluva.
You may also be interested in...
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
Pharmacopeia gets Bristol exec
Rene Belder, who led Bristol-Myers Squibb's regulatory team for the PPAR agonist Pargluva (muraglitazar), joins Pharmacopeia as VP-clinical and regulatory affairs, the Princeton, N.J. biotech announces Nov. 6. Bristol halted development of Pargluva in May, seven months after an FDA "approvable" letter for the diabetes agent suggested additional clinical trials would be necessary (1"The Pink Sheet" Dec. 19, 2005, p. 11). At Pharmacopeia, Belder will be responsible for overseeing the firm's current and future clinical development product portfolio...